Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 362 | 49 | 311 |
| Samples | 306 | 44 | 260 |
| Peptides | 143 | 33 | 126 |
Function
KRTAP4-9 · Keratin associated protein 4-9
Involved in aging and hair cycle. Predicted to be located in cytosol. [provided by Alliance of Genome Resources, Apr 2022]
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000391415 | Q9BYQ8 | 362 | 143 |
Gene Properties
Recurrent Mutations
All 143 amino-acid changes on canonical ENST00000391415 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KRTAP4-9 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KRTAP4-9 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chordoma | 2/7 29% | 0/13 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 8/133 6% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 13/612 2% |
| Colorectal Carcinoma | 7/143 5% | 42/3239 1% |
| Other Solid Cancers | 2/94 2% | 20/1515 1% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 14/1390 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 20/1592 1% |
| Melanoma | 1/210 0% | 20/1899 1% |
| Osteosarcoma | 0/45 0% | 2/166 1% |
| Adrenocortical Carcinoma | 1/3 33% | 0/112 0% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 5/810 1% |
| Bladder Carcinoma | 0/58 0% | 7/956 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Prostate Carcinoma | 0/13 0% | 13/2105 1% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 13/2534 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Biliary Tract Carcinoma | 1/54 2% | 4/950 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Hepatocellular Carcinoma | 0/46 0% | 11/2210 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 9/2550 0% |
| Other Blood Cancers | 0/61 0% | 9/2725 0% |
| Head and Neck Carcinoma | 3/85 4% | 2/1574 0% |
Mutation Distribution
Where KRTAP4-9 is mutated · all tissues, split by cell line vs tissue
How many mutations in KRTAP4-9 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 2 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 362 mutations in KRTAP4-9
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|